Taken together, the efficacy outcomes from different stages of PCa and parallel molecular assessments indicated that IP6 feeding could impact tumor metabolism via interfering in glucose uptake (due to its effect on GLUT-4 expression) which in turn could slow down tumor proliferation early on. The gene discussed is SLC2A4; the disease is posterior cortical atrophy.